

Table F-5. Key findings in studies of risperidone adjuncts

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
<p>Ghaleiha et al., 2015⁶⁰ RCT</p> <p>G1: Risperidone + pioglitazone (up to 2 mg/day + 30 mg/day), 22/20 G2: Risperidone + placebo (NA), 22/20</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 6.95 ± 2.40 G2: 6.20 ± 1.32</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 18.25 ± 4.38 G2: 19.00 ± 5.70</p> <p>ABC-Lethargy G1: 15.05 ± 7.56 G2: 13.66 ± 7.26</p> <p>ABC-Stereotypic behavior G1: 7.70 ± 4.61 G2: 9.40 ± 5.28</p> <p>ABC-Hyperactivity G1: 25.00 ± 10.05 G2: 27.86 ± 9.85</p> <p>ABC-Inappropriate speech G1: 5.70 ± 3.60 G2: 4.70 ± 3.78</p>	<p>Change scores from baseline</p> <p>ABC-Irritability G1: 10.20 ± 5.87 G2: 5.90 ± 5.04 G1 vs G2: p=0.03</p> <p>ABC-Lethargy G1: 3.75 ± 4.69 G2: 1.05 ± 2.96 G1 vs G2: p=0.04</p> <p>ABC-Stereotypic behavior G1: 2.10 ± 2.90 G2: 1.40 ± 1.98 G1 vs G2: p=ns</p> <p>ABC-Hyperactivity G1: 10.15 ± 6.42 G2: 5.30 ± 7.76 G1 vs G2: p=0.04</p> <p>ABC-Inappropriate speech G1: 1.40 ± 3.20 G2: 0.70 ± 1.45 G1 vs G2: p=ns</p> <p>Treatment responses: n (%) Partial response (≥ 25% reduction in irritability score): G1: 9 (45) G2: 3 (15) G1 vs. G2: p=0.04</p> <p>Complete response (≥ 50% reduction in irritability score): G1: 9 (45) G2: 7 (35) G1 vs. G2: p=ns</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
<p>Ghanizadeh et al., 2015⁶¹ RCT</p> <p>G1: Risperidone + buspirone (up to 3 mg/day + up to 20 mg/kg), 20/16 G2: Risperidone + placebo (NA), 20/18</p> <p>8 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 7.05 ± 2.3 G2: 7.5 ± 2.6</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 25.7 ± 5.7 G2: 24.7 ± 7.6</p>	<p>EOT ABC-Irritability G1: 16.6 ± 7.6 G2: 18.2 ± 7.7</p> <p>Treatment response, n (%) >25% reduction in irritability score: n (%): G1: 13 (81.2) G2: 8 (44.4) G1 vs. G2: p<0.02, RR=1.82</p> <p>≥ 30% reduction in irritability score: G1: 13 (81.2) G2: 7 (38.9) G1 vs. G2: p<0.01, RR=2.1</p>
<p>Nikoo et al., 2015⁶² RCT</p> <p>G1: Risperidone + N-acetylcysteine (1-2.0 mg/day + 600-900 mg/day), 25/20 G2: Risperidone + placebo (NA), 25/20</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 7.50 ± 2.63 G2: 7.60 ± 2.60</p> <p>IQ G1: NR G2: NR</p>	<p>ABC-Irritability G1: 21.20 ± 5.16 G2: 19.70 ± 7.61</p> <p>ABC-Lethargy G1: 21.10 ± 6.39 G2: 20.65 ± 9.62</p> <p>ABC-Stereotypic behavior G1: 10.55 ± 4.22 G2: 10.05 ± 5.35</p> <p>ABC-Hyperactivity G1: 27.65 ± 6.16 G2: 25.10 ± 9.44</p> <p>ABC-Inappropriate speech G1: 5.70 ± 2.92 G2: 4.75 ± 3.72</p>	<p>EOT ABC-Irritability G1: 11.95 ± 4.87 G2: 14.35 ± 6.27 G1 vs G2: p<0.05</p> <p>ABC-Lethargy G1: 17.15 ± 5.46 G2: 17.95 ± 8.40 G1 vs G2: p=ns</p> <p>ABC-Stereotypic behavior G1: 7.75 ± 4.90 G2: 8.70 ± 5.44 G1 vs G2: p=ns</p> <p>ABC-Hyperactivity G1: 21.45 ± 8.47 G2: 23.05 ± 9.03 G1 vs G2: p<0.05</p> <p>ABC-Inappropriate speech G1: 4.95 ± 2.85 G2: 4.80 ± 3.47 G1 vs G2: p=ns</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
<p>Ghanizadeh, et al., 2013⁶⁵ RCT</p> <p>G1: Risperidone + N-acetylcysteine (up to 3 mg/day + 1200 mg/day), 20/17 G2: Risperidone + placebo (NA), 20/14</p> <p>8 weeks/EOT</p> <p>Low RoB</p>	<p>Age: G1: 8.8 ± 3.1 G2: 7.9 ± 2.4</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 13.2 ± 5.3 G2: 16.7 ± 7.8</p> <p>ABC-Hyperactivity G1: 29.3 ± 6.4 G2: 31.9 ± 8.9</p> <p>ABC-Lethargy G1: 11.9 ± 6.5 G2: 12.2 ± 8.3</p> <p>ABC-Stereotypic behavior G1: 6.6 ± 4.5 G2: 8.5 ± 6.3</p> <p>ABC-Inappropriate speech G1: 3.9 ± 3.7 G2: 5.7 ± 3.8</p>	<p>EOT</p> <p>ABC-Irritability G1: 9.7 ± 4.1 G2: 15.1 ± 7.8 G1 vs G2: p<0.035</p> <p>ABC-Hyperactivity G1: 18.3 ± 6.9 G2: 24.3 ± 12.1 G1 vs G2: p=ns</p> <p>ABC-Lethargy G1: 8.5 ± 6.5 G2: 10.9 ± 7.6 G1 vs G2: p=ns</p> <p>ABC-Stereotypic behavior G1: 3.9 ± 2.7 G2: 7.8 ± 6.6 G1 vs G2: p=ns</p> <p>ABC-Inappropriate speech G1: 3.2 ± 3.4 G2: 5.2 ± 4.0 G1 vs G2: p=ns</p>
<p>Asadabadi, et al., 2013⁶⁴ RCT</p> <p>G1: Risperidone + celecoxib (up to 3 mg/day + up to 300 mg/day), 20/20 G2: Risperidone + placebo (NA), 20/20</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 7.6 ± 1.7 G2: 7.5 ± 1.5</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 17.3 ± 1.6 G2: 17.6 ± 2.4</p> <p>ABC-Lethargy G1: 17.0 ± 3.0 G2: 17.1 ± 3.2</p> <p>ABC-Stereotypic behavior G1: 9.1 ± 2.2 G2: 9.2 ± 2.3</p> <p>ABC-Hyperactivity G1: 22.0 ± 2.9 G2: 22.6 ± 3.0</p> <p>ABC-Inappropriate speech G1: 5.4 ± 1.4 G2: 5.5 ± 0.9</p>	<p>EOT</p> <p>ABC-Irritability G1: 8.7 ± 1.6 G2: 12.4 ± 3.0 G1 vs G2: p<0.001</p> <p>ABC-Lethargy G1: 9.9 ± 3.1 G2: 14.3 ± 2.1 G1 vs G2: p<0.001</p> <p>ABC-Stereotypic behavior G1: 4.0 ± 1.2 G2: 6.9 ± 2.3 G1 vs G2: p<0.001</p> <p>ABC-Hyperactivity G1: 11.2 ± 2.1 G2: 12.9 ± 2.6 G1 vs G2: p=ns</p> <p>ABC-Inappropriate speech</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years \pm SD</p> <p>Mean IQ \pmSD</p>	<p>Outcome measure/Baseline scores, mean \pmSD</p>	<p>Outcome measure/Post- treatment scores, mean \pm SD</p>
			<p>G1: 4.1 \pm 2.0 G2: 4.3 \pm 1.2 G1 vs G2: p=ns</p>
<p>Ghaleiha, et al., 2013⁶⁵ RCT</p> <p>G1: Risperidone + memantine (up to 3 mg/day + up to 20 mg/day), 20/20 G2: Risperidone + placebo (NA), 20/20</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 7.42 \pm 1.48 G2: 7.97 \pm 1.68</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 18.25 \pm 1.55 G2: 17.65 \pm 3.74</p> <p>ABC-Lethargy G1: 16.55 \pm 4.26 G2: 16.85 \pm 3.48</p> <p>ABC-Stereotypic behavior G1: 8.83 \pm 3.08 G2: 8.26 \pm 2.67</p> <p>ABC-Hyperactivity G1: 23.00 \pm 4.69 G2: 22.45 \pm 7.91</p> <p>ABC-Inappropriate speech G1: 6.00 \pm 1.36 G2: 5.85 \pm 1.46</p>	<p>EOT ABC-Irritability G1: 8.90 \pm 1.55 G2: 12.75 \pm 3.05 G1 vs G2: p<0.01</p> <p>ABC-Lethargy G1: 11.65 \pm 3.39 G2: 13.85 \pm 2.10 G1 vs G2: p=ns</p> <p>ABC-Stereotypic behavior G1: 3.30 \pm 1.30 G2: 6.99 \pm 1.97 G1 vs G2: p<0.01</p> <p>ABC-Hyperactivity G1: 8.25 \pm 2.19 G2: 13.85 \pm 3.28 G1 vs G2: p=<0.01</p> <p>ABC-Inappropriate speech G1: 4.50 \pm 1.75 G2: 4.69 \pm 1.60 G1 vs G2: p=ns</p>
<p>Ghaleiha, et al., 2013⁶⁶ RCT</p> <p>G1: Risperidone + riluzole (up to 3 mg/day + up to 100 mg/day), 25/20 G2: Risperidone + placebo (NA), 24/20</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 8.4 \pm 2.3 G2: 7.6 \pm 1.7</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 21.40 \pm 4.18 G2: 22.10 \pm 9.98</p> <p>ABC-Lethargy G1: 23.95 \pm 8.04 G2: 24.30 \pm 10.98</p> <p>ABC-Stereotypic behavior G1: 7.80 \pm 3.43 G2: 8.25 \pm 4.93</p>	<p>EOT ABC-Irritability G1: 11.85 \pm 5.57 G2: 16.25 \pm 7.86 G1 vs G2: p=0.03</p> <p>Treatment responses: n (%) Partial response (\geq 25% reduction in irritability score): G1: 17 (85)</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
		<p>ABC-Hyperactivity G1: 26.35 ± 7.67 G2: 27.95 ± 10.68</p> <p>ABC-Inappropriate speech G1: 5.85 ± 3.38 G2: 5.80 ± 3.10</p>	<p>G2: 8 (40) G1 vs. G2: p=0.003</p> <p>Complete response (≥ 50% reduction in irritability score): G1: 7 (35) G2: 3 (15) G1 vs. G2: p=ns</p> <p>ABC-Lethargy G1: 17.10 ± 5.98 G2: 21.45 ± 9.43 G1 vs G2: p=0.02</p> <p>ABC-Stereotypic behavior G1: 4.90 ± 3.49 G2: 7.75 ± 5.10 G1 vs G2: p=0.03</p> <p>ABC-Hyperactivity G1: 20.35 ± 9.15 G2: 26.65 ± 9.97 G1 vs G2: p=0.005</p> <p>ABC-Inappropriate speech G1: 4.95 ± 3.20 G2: 5.70 ± 2.51 G1 vs G2: p=ns</p> <p>CGI – Very Much Improved G1: 3 (15) G2: 1 (5)</p> <p>CGI – Much Improved G1: 8 (40) G2: 4 (20)</p> <p>CGI-responders: G1:11 (55) G2: 5 (25) G1 Vs. G2, p=0.05</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years \pm SD</p> <p>Mean IQ \pmSD</p>	<p>Outcome measure/Baseline scores, mean \pmSD</p>	<p>Outcome measure/Post- treatment scores, mean \pm SD</p>
<p>Ghaleiha 2013⁶⁷ RCT</p> <p>G1: Galantamine + Risperidone (2-24 mg/day + 0.5-2 mg/day), 23/20 G2: Risperidone + Placebo (0.5-2mg/day), 23/20</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 6.85 \pm 1.98 G2: 5.90 \pm 1.38</p> <p>IQ NR</p>	<p>ABC-C-Irritability G1: 15.59 \pm 5.83 G2: 14.95 \pm 4.38</p> <p>ABC-C-Lethargy/Social withdrawal G1: 11.10 \pm 5.34 G2: 10.40 \pm 5.27</p> <p>ABC-C-Stereotypical behavior G1: 6.10 \pm 5.93 G2: 5.80 \pm 5.08</p> <p>ABC-C-Hyperactivity/noncompliance G1: 20.85 \pm 11.69 G2: 22.30 \pm 9.83</p> <p>ABC-C-Inappropriate Speech G1: 3.50 \pm 3.95 G2: 3.25 \pm 4.43</p>	<p>EOT</p> <p>ABC-C-Irritability G1: 5.30 \pm 4.25 G2: 8.80 \pm 5.03 G1 vs G2: p=0.017</p> <p>ABC-C-Lethargy/Social Withdrawal G1: 5.60 \pm 4.43 G2: 8.35 \pm 5.59 G1 vs G2: p=0.003</p> <p>ABC-C-Stereotypical Behavior G1: 3.95 \pm 5.06 G2: 4.50 \pm 4.34 G1 vs G2: p=ns</p> <p>ABC-C-Hyperactivity/noncompliance G1: 10.85 \pm 9.49 G2: 16.05 \pm 7.52 G1 vs G2: p=ns</p> <p>ABC-C-Inappropriate Speech G1: 2.15 \pm 2.68 G2: 2.80 \pm 3.63 G1 vs G2: p=ns</p>
<p>Mohammadi, et al., 2013⁶⁸ RCT</p> <p>G1: Risperidone + amantadine (up to 2 mg/day + up to 150 mg/day), 20/20 G2: Risperidone + placebo (NA), 20/19</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 6.4 \pm 2.3 G2: 7.1 \pm 2.4</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 20.00 \pm 5.30 G2: 20.90 \pm 6.61</p> <p>ABC-Lethargy G1: 18.55 \pm 7.13 G2: 18.15 \pm 4.80</p> <p>ABC-Stereotypic behavior G1: 10.90 \pm 4.03 G2: 11.30 \pm 5.42</p> <p>ABC-Hyperactivity G1: 28.15 \pm 6.88 G2: 28.55 \pm 8.67</p> <p>ABC-Inappropriate speech G1: 5.70 \pm 3.11 G2: 4.55 \pm 3.48</p>	<p>Change (reduction from baseline)</p> <p>ABC-Irritability G1: 8.60 \pm 4.65 G2: 5.35 \pm 3.95 p=0.02</p> <p>ABC-Lethargy G1: 1.35 \pm 3.18 G2: 1.30 \pm 3.33 p=ns</p> <p>ABC-Stereotypic behavior G1: 1.20 \pm 2.33 G2: 1.20 \pm 2.09 p=ns</p> <p>ABC-Hyperactivity G1: 6.15 \pm 5.11 G2: 2.50 \pm 5.00</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
			<p>P=0.03</p> <p>ABC-Inappropriate speech G1: 0.40 ± 0.99 G2: 0.05 ± 0.22 p=ns</p> <p>CGI Very much improved, n: G1: 2 G2: 1</p> <p>Much improved, n: G1: 8 G2: 3</p> <p>Improvement, n (%): G1: 10 (50) G2: 4 (20) G1 vs. G2: p=0.047</p>
<p>Hasanzadeh, et al., 2012⁶⁹ RCT</p> <p>G1: Risperidone + Ginko T.D (up to 3 mg/day + up to 120 mg/day), 23/23 G2: Risperidone + placebo (NA), 24/ 24</p> <p>10 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 6.04 ± 1.61 G2: 6.76 ± 2.60</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 14.95 ± 7.86 G2: 14.08 ± 7.55</p> <p>ABC-Lethargy G1: 11.63 ± 7.90 G2: 12.32 ± 9.38</p> <p>ABC-Stereotypic behavior G1: 6.77 ± 4.42 G2: 6.32 ± 4.11</p> <p>ABC-Hyperactivity G1: 22.68 ± 9.88 G2: 21.36 ± 6.96</p> <p>ABC-Inappropriate speech G1: 3.36 ± 1.96 G2: 3.92 ± 2.11</p>	<p>EOT</p> <p>ABC-Irritability G1: 10.54 ± 5.75 G2: 9.88 ± 7.35 G1 vs G2: p=ns</p> <p>ABC-Lethargy G1: 6.86 ± 6.08 G2: 7.36 ± 6.14 G1 vs G2: p=ns</p> <p>ABC-Stereotypic behavior G1: 4.7 ± 23.28 G2: 5.00 ± 3.80 G1 vs G2: p=ns</p> <p>ABC-Hyperactivity G1: 16.54 ± 8.51 G2: 14.84 ± 6.25 G1 vs G2: p=ns</p> <p>ABC-Inappropriate speech G1: 2.09 ± 1.63 G2: 2.44 ± 1.58 G1 vs G2: p=ns</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
<p>Akhondzadeh, et al., 2010⁷⁰ RCT</p> <p>G1: Risperidone + pentoxifylline (up to 3 mg/day + up to 600 mg/day), 20/20 G2: Risperidone + placebo (NA), 20/20</p> <p>10 weeks/EOT</p> <p>Moderate RoB</p>	<p>Age: G1: 8.05 ± 2.01 G2: 7.37 ± 2.41</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 16.67 ± 2.71 G2: 16.06 ± 3.00</p> <p>ABC-Lethargy G1: 18.27 ± 2.97 G2: 17.29 ± 3.23</p> <p>ABC-Stereotypic behavior G1: 8.01 ± 1.30 G2: 7.72 ± 1.44</p> <p>ABC-Hyperactivity G1: 16.03 ± 2.60 G2: 15.44 ± 2.88</p> <p>ABC-Inappropriate speech G1: 5.13 ± 0.83 G2: 4.94 ± 0.92</p>	<p>EOT</p> <p>ABC-Irritability G1: 7.14 ± 3.23 G2: 11.65 ± 1.72 Group X time: p≤0.0001</p> <p>ABC-Lethargy G1: 8.03 ± 3.64 G2: 13.05 ± 1.93 Group X time: p≤0.0001</p> <p>ABC-Stereotypic behavior G1: 3.57 ± 1.61 G2: 5.59 ± 0.82 Group X time: p≤0.0001</p> <p>ABC-Hyperactivity G1: 8.92 ± 4.05 G2: 12.59 ± 1.86 Group X time: p≤0.0001</p> <p>ABC-Inappropriate speech G1: 2.08 ± 0.94 G2: 3.73 ± 0.55 Group X time: p≤0.0001</p>
<p>Ghaleiha et al., 2016⁷¹ RCT</p> <p>G1: Risperidone + Minocycline (up to 2mg/day + 50 mg 2/day), 25/23 G2: Risperidone + Placebo (up to 2 mg/day + 1 capsule 2/day), 25/23</p> <p>10 weeks/EOT</p> <p>Low ROB</p>	<p>Age G1: 7.39 ± 2.48 G2: 7.78 ± 2.59</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 21.26 ± 4.82 G2: 19.91 ± 7.2</p> <p>ABC-Social Withdrawal/Lethargy G1: 21.39 ± 6.05 G2: 20.3 ± 9.12</p> <p>ABC-Stereotypic Behavior G1: 10.96 ± 4.09 G2: 11.09 ± 5.77</p> <p>ABC-Hyperactivity G1: 28.22 ± 5.97 G2: 25.04 ± 9.04</p> <p>ABC-Inappropriate</p>	<p>ABC-Irritability G1: 12.09 ± 4.55 G2: 14.04 ± 5.98 G1 vs G2, p=0.003; d=0.91; MD (95% CI) = 3.30 (1.15–5.46)</p> <p>ABC-Social Withdrawal/Lethargy G1: 17.87 ± 5.69 G2: 17.7 ± 8.18 G1 vs G2, p=ns; d=0.22; MD (95% CI) = 0.91 (-1.57 to 4.00)</p> <p>ABC-Stereotypic Behavior G1: 8.22 ± 4.81</p>

<p>Author, Year Study Design</p> <p>Groups (dose), N enrollment / N final</p> <p>Treatment duration/Follow-up timepoint post-treatment</p> <p>Risk of Bias</p>	<p>Mean age, years ± SD</p> <p>Mean IQ ±SD</p>	<p>Outcome measure/Baseline scores, mean ±SD</p>	<p>Outcome measure/Post- treatment scores, mean ± SD</p>
		<p>Speech G1: 6.17 ± 3.01 G2: 5.04 ± 3.56</p>	<p>G2: 9.43 ± 5.69 G1 vs G2, p=ns; d=0.36; MD (95% CI) = 1.08 (-0.68 to 2.86)</p> <p>ABC-Hyperactivity G1: 21.3 ± 7.9 G2: 22.91 ± 8.98 G1 vs G2, p=0.002; d=0.95; MD (95% CI) = 4.78 (1.80– 7.70)</p> <p>ABC-Inappropriate Speech G1: 5.35 ± 2.9 G2: 4.78 ± 3.45 G1 vs G2, p=ns; d=0.34; MD (95% CI) = 0.56 (-0.40 to 1.53)</p>
<p>Rezaei, et al., 2010⁷² RCT</p> <p>G1: Risperidone + topiramate (up to 3 mg/day + up to 200 mg/day), 20/20 G2: Risperidone + placebo (NA), 20/20</p> <p>8 weeks/EOT</p> <p>Low RoB</p>	<p>Age G1: 8.17 ± 1.85 G2: 7.85 ± 1.82</p> <p>IQ NR</p>	<p>ABC-Irritability G1: 17.25 ± 3.12 G2: 16.80 ± 4.22</p> <p>ABC-Lethargy G1: 17.65 ± 6.02 G2: 17.55 ± 4.28</p> <p>ABC-Stereotypic behavior G1: 8.83 ± 3.89 G2: 8.71 ± 3.21</p> <p>ABC-Hyperactivity G1: 22.75 ± 4.85 G2: 22.00 ± 9.17</p> <p>ABC-Inappropriate speech G1: 5.25 ± 2.01 G2: 5.10 ± 1.80</p>	<p>EOT ABC-Irritability G1: 8.20 ± 2.44 G2: 15.30 ± 4.64 G1 vs G2: p=0.04</p> <p>ABC-Lethargy G1: 14.15 ± 6.67 G2: 15.60 ± 4.28 G1 vs G2: p=ns</p> <p>ABC-Stereotypic behavior G1: 3.40 ± 1.04 G2: 8.09 ± 3.04 G1 vs G2: p=0.04</p> <p>ABC-Hyperactivity G1: 7.60 ± 2.37 G2: 19.25 ± 8.30 G1 vs G2: p=0.04</p> <p>ABC-Inappropriate speech G1: 3.93 ± 2.17 G2: 4.24 ± 1.59 G1 vs G2: p=ns</p>

Author, Year Study Design Groups (dose), N enrollment / N final Treatment duration/Follow-up timepoint post-treatment Risk of Bias	Mean age, years ± SD Mean IQ ±SD	Outcome measure/Baseline scores, mean ±SD	Outcome measure/Post- treatment scores, mean ± SD
Akhondzadeh et al., 2008 ⁷³ RCT G1: Risperidone + Piracetam (+ 3 mg/day + 800 mg/day), 20/20 G2: Risperidone + Placebo (NA), 20/20 10 weeks/EOT Moderate RoB	Age G1: 6.90 ± 1.86 G2: 6.75 ± 1.80 IQ NR	ABC-Community Total Score G1: 23.15 ± 5.8 G2: 24 ± 8.25	Mean change score from baseline ABC-Community Total Score G1: -11.9 ± 3.79 G2: -5.15 ± 3.04 G1 vs G2, p<0.0001

EOT-End of Treatment; ABC-Aberrant Behavior Checklist; CGI-Clinical Global Impression